Show simple item record

dc.contributor.authorBranigan, G.L.
dc.contributor.authorTorrandell-Haro, G.
dc.contributor.authorSoto, M.
dc.contributor.authorGelmann, E.P.
dc.contributor.authorVitali, F.
dc.contributor.authorRodgers, K.E.
dc.contributor.authorBrinton, R.D.
dc.date.accessioned2022-04-11T23:18:12Z
dc.date.available2022-04-11T23:18:12Z
dc.date.issued2022
dc.identifier.citationBranigan, G. L., Torrandell-Haro, G., Soto, M., Gelmann, E. P., Vitali, F., Rodgers, K. E., & Brinton, R. D. (2022). Androgen-targeting therapeutics mitigate the adverse effect of GnRH agonist on the risk of neurodegenerative disease in men treated for prostate cancer. Cancer Medicine.
dc.identifier.issn2045-7634
dc.identifier.doi10.1002/cam4.4650
dc.identifier.urihttp://hdl.handle.net/10150/663954
dc.description.abstractBackground: Prostate cancer and multiple neurodegenerative diseases (NDD) share an age-associated pattern of onset. Therapy of prostate cancer is known to impact cognitive function. The objective of this study was to determine the impact of multiple classes of androgen-targeting therapeutics (ATT) on the risk of NDD. Methods: A retrospective cohort study of men aged 45 and older with prostate within the US-based Mariner claims data set between January 1 and 27, 2021. A propensity score approach was used to minimize measured and unmeasured selection bias. Disease risk was determined using Kaplan–Meier survival analyses. Results: Of the 1,798,648 men with prostate cancer, 209,722 met inclusion criteria. Mean (SD) follow-up was 6.4 (1.8) years. In the propensity score-matched population, exposure to ATT was associated with a minimal increase in NDD incidence (relative risk [RR], 1.07; 95% CI, 1.05–1.10; p < 0.001). However, GnRH agonists alone were associated with significantly increased NDD risk (RR, 1.47; 95% CI, 1.30–1.66; p <0.001). Abiraterone, commonly administered with GnRH agonists and low-dose prednisone, was associated with a significantly decreased risk (RR, 0.77; 95% CI, 0.68–0.87; p < 0.001) of any NDD. Conclusions: Among patients with prostate cancer, GnRH agonist exposure was associated with an increased NDD risk. Abiraterone acetate reduced the risks of Alzheimer's disease and Parkinson's disease conferred by GnRH agonists, whereas the risk for ALS was reduced by androgen receptor inhibitors. Outcomes of these analyses contribute to addressing controversies in the field and indicate that GnRH agonism may be a predictable instigator of risk for NDD with opportunities for risk mitigation in combination with another ATT. © 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
dc.language.isoen
dc.publisherJohn Wiley and Sons Inc
dc.rightsCopyright © 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution License.
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectabiraterone
dc.subjectAlzheimer's disease
dc.subjectandrogen
dc.subjectmedical informatics
dc.subjectneurodegenerative disease
dc.subjectprostate cancer
dc.titleAndrogen-targeting therapeutics mitigate the adverse effect of GnRH agonist on the risk of neurodegenerative disease in men treated for prostate cancer
dc.typeArticle
dc.typetext
dc.contributor.departmentCenter for Innovation in Brain Science, University of Arizona
dc.contributor.departmentDepartment of Pharmacology, University of Arizona College of Medicine
dc.contributor.departmentMedical Scientist Training Program, University of Arizona College of Medicine
dc.contributor.departmentDepartment of Medicine, Division of Hematology and Oncology, University of Arizona College of Medicine
dc.contributor.departmentUniversity of Arizona Cancer Center
dc.contributor.departmentDepartment of Neurology, University of Arizona College of Medicine
dc.identifier.journalCancer Medicine
dc.description.noteOpen access journal
dc.description.collectioninformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.
dc.eprint.versionFinal published version
dc.source.journaltitleCancer Medicine
refterms.dateFOA2022-04-11T23:18:12Z


Files in this item

Thumbnail
Name:
CancerMedicine_2022_Branigan.pdf
Size:
1010.Kb
Format:
PDF
Description:
Final Published Version

This item appears in the following Collection(s)

Show simple item record

Copyright © 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution License.
Except where otherwise noted, this item's license is described as Copyright © 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution License.